Satralizumab (neuromyelitis optica spectrum disorders in anti-aquaporin-4 IgG (AQP4-IgG) seropositive patients ≥ 12 years of age)

Subject:

• Active Substance: Satralizumab
• Name: Enspryng^®
• Therapeutic area: Neuromyelitis optica spectrum disorders
• Pharmaceutical company: Roche Pharma AG

Time table:

• Start: 15.07.2021
• Final decision by G-BA: 06.01.2022

Final decision:

• Hint for a minor additional benefit (orphan drug)